Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

Brentuximab Vedotin 20Rituximab 10pirtobrutinib 7dacetuzumab 7Doxorubicin 6ruxolitinib 5Vincristine 5Prednisone 5Lenalidomide 5Cyclophosphamide 5ponatinib 4Imatinib Mesylate 4Dexamethasone 4Bendamustine Hydrochloride 4Azacitidine 4nilotinib 3lintuzumab 3Bortezomib 3vosaroxin 2venetoclax 2spartalizumab 2pomalidomide 2ibrutinib 2Rifampin 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2KW-2478 2Ifosfamide 2Gemcitabine 2Etoposide 2Dacarbazine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Diseases × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡